{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nowak JK"],"funding":["European Union’s Seventh Framework Programme","European Union's Seventh Framework Programme","Medical Research Council","Polish National Science Centre","Crohn's and Colitis UK"],"pagination":["1255-1268"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9426667"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(8)"],"pubmed_abstract":["Aim
To assess the pathobiological and translational importance of whole-blood transcriptomic analysis in inflammatory bowel disease [IBD].Methods
We analysed whole-blood expression profiles from paired-end sequencing in a discovery cohort of 590 Europeans recruited across six countries in the IBD Character initiative (newly diagnosed patients with Crohn's disease [CD; n = 156], ulcerative colitis [UC; n = 167], and controls [n = 267]), exploring differential expression [DESeq2], co-expression networks [WGCNA], and transcription factor involvement [EPEE, ChEA, DoRothEA]. Findings were validated by analysis of an independent replication cohort [99 CD, 100 UC, 95 controls]. In the discovery cohort, we also defined baseline expression correlates of future treatment escalation u"],"journal":["Journal of Crohn's & colitis"],"pubmed_title":["Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2."],"pmcid":["PMC9426667"],"funding_grant_id":["2858546","MR/S034919/1","G0701898","2017/25/B/NZ5/02783","M2018-2 Ho"],"pubmed_authors":["Kalla R","A Dahl F","Nimmo ER","Nowak JK","Casen C","Torkvist L","Hjelm F","Shand AG","Satsangi J","Frengen AB","Soderholm JD","Ostrowski J","Gut IG","Bonfiglio F","Lindstrom JC","Carstens A","Olbjorn C","Ekeland GS","Lindahl T","Detlie TE","Hjortswang H","Noble CL","Bergemalm D","Ventham NT","Ciemniejewska E","Ekman D","Poncelet D","Walkowiak J","Ho GT","Solvernes J","IBD Character Consortium","Vatn S","Andersson E","Gullberg M","Sundell M","Nordberg N","Ocklind A","Arnott ID","Halfvarson J","Gomollon F","Schoemans R","D'Amato M","Pierik M","Gut M","Pettersson E","Sabatel C","Wilson DC","Jahnsen J","Merkel A","Boyapati RK","Kennedy NA","Heath SC","Lees CW","Jonkers D","Lindqvist M","Vatn MH","Moen AEF","Nilsen H","Bayes M","Keita AV","Veillard AC","You P","Drummond HE","Adams AT","Modig E","O'Leary KR","Tannæs TM","Repsilber D","Ricanek P"],"additional_accession":[]},"is_claimable":false,"name":"Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.","description":"Aim
To assess the pathobiological and translational importance of whole-blood transcriptomic analysis in inflammatory bowel disease [IBD].Methods
We analysed whole-blood expression profiles from paired-end sequencing in a discovery cohort of 590 Europeans recruited across six countries in the IBD Character initiative (newly diagnosed patients with Crohn's disease [CD; n = 156], ulcerative colitis [UC; n = 167], and controls [n = 267]), exploring differential expression [DESeq2], co-expression networks [WGCNA], and transcription factor involvement [EPEE, ChEA, DoRothEA]. Findings were validated by analysis of an independent replication cohort [99 CD, 100 UC, 95 controls]. In the discovery cohort, we also defined baseline expression correlates of future treatment escalation u","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-31T17:00:15.598Z","creation":"2024-11-07T03:06:56.009Z"},"accession":"S-EPMC9426667","cross_references":{"pubmed":["35212366"],"doi":["10.1093/ecco-jcc/jjac033"]}}